Absci Corporation
NASDAQ:ABSIBiotechnology
Healthcare
$8.18 +1.04%
+$0.08 today
- Market cap
- $1.41B
- Beta
- 2.46
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$0.77
52W Low $2.24High $8.17
Volume 5.66M
Average 5.10M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$92.92M
FY 2025 · Annual
Investing Cash Flow
-$50.16M
FY 2025 · Annual
Financing Cash Flow
$105.95M
FY 2025 · Annual
+28.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.96M) | (104.9M) | (110.57M) | (103.11M) | (115.18M) |
| Depreciation & Amortization | 6.65M | 13.1M | 14M | 13.39M | 11.74M |
| Deferred Income Tax | (8.9M) | (505K) | (52K) | 0 | 0 |
| Stock-Based Compensation | 10.61M | 12.54M | 11.42M | 19.45M | 18.32M |
| Change in Working Capital | (3.15M) | (1.54M) | 1.52M | (368K) | 423K |
| Accounts Receivables | 230K | (148K) | (666K) | 2.24M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (533K) | (786K) | 2.03M | 1.09M |
| Other Working Capital | (4.95M) | (859K) | 2.97M | (4.63M) | (671K) |
| Other Non-Cash Items | 35.15M | (30K) | 19.05M | (1.77M) | (8.23M) |
| Operating Cash Flow | (60.6M) | (81.34M) | (64.64M) | (72.4M) | (92.93M) |
| Capital Expenditures | (38.05M) | (16.18M) | (860K) | (404K) | (1.11M) |
| Acquisitions (Net) | (28.13M) | (8M) | 0 | 0 | 1.31M |
| Purchases of Investments | (1.2M) | (108.59M) | (147.35M) | (186.11M) | (119.87M) |
| Sales of Investments | 0 | 5M | 229.9M | 144M | 69.5M |
| Other Investing Activities | 0 | 783K | 254K | 939K | 0 |
| Investing Cash Flow | (67.38M) | (126.98M) | 81.94M | (41.58M) | (50.16M) |
| Debt Repayment | 120.85M | 4.58M | (5.35M) | (4.03M) | (3.2M) |
| Common Stock Issued | 210.4M | 656K | 862K | 86.56M | 109.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 336.19M | 5.24M | (4.48M) | 82.53M | 105.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 208.22M | (203.08M) | 12.83M | (31.45M) | (37.14M) |
| Free Cash Flow | (98.65M) | (97.51M) | (65.5M) | (72.81M) | (94.03M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$115.2M
+ D&A$11.7M
+ Stock-Based Comp$18.3M
+ Deferred Tax$0
+ Working Capital$423.0K
- Other Non-Cash-$8.2M
= Operating Cash Flow-$92.9M
- Capex-$1.1M
= Free Cash Flow-$94.0M
Analysis
FY2025 free cash flow is -$94.0M. FCF conversion is 81.6% of net income. Operating cash flow was -$92.9M, with capex of -$1.1M. The largest bridge item is Stock-Based Comp at $18.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| S-3ASR | S-3ASR filing | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 |
Does ABSI generate free cash flow?
Absci Corporation (ABSI) generated -$94.03M of free cash flow in fiscal 2025.
How much operating cash flow does ABSI produce?
Operating cash flow was -$92.92M, before capital expenditures of $1.11M.
Continue the stock analysis
Jump to another research area for this company.